



<http://www.orientjchem.org>

Synthesis and Biological Studies of Pyrazolo [3, 4-d] Pyrimidines

P.K. CHAUDHARI, K.H.SIKOTRA and V.H. SHAH

Shri R.R.Lalan College, Chemistry Department, Bhuj-Kutch - 370 001 (India).
E-mail: Parthivkantilal@gmail.com

(Received: October 12, 2010; Accepted: November 15, 2010)

ABSTRACT

An novel series of the pyrazolo [3,4-d] pyrimidines (IIIa-n) were prepared via one pot reaction of 4-amino-5-cyano-6-aryl-2- mercapto-5,6-dihydro pyrimidines(I) with hydrazine hydrate(II) in ethanol. Elemental analysis, IR, ¹NMR and mass spectral data established identification of the compounds (IIIa-n) was evaluated for their antimicrobial activity. Some of the obtained compounds showed the interesting antimicrobial activity comparable to standard drugs like ampicillin, chloramphenicol, amoxicillin, ciprofloxacin, norfloxacin and griseoflavin.

Key words: pyrazolo [3, 4-d] pyrimidines, Antimicrobial activity and Antituberculosis activity, Antimycobacterial activity.

INTRODUCTION

pyrazolo [3,4-d] pyrimidines are of considerable chemical and pharmaceutical importance as purines analogs¹⁻³ of naturally occurring fused uracils that possess diverse biological activities⁴. These derivatives⁵⁻⁸ were found to be selective ligands with antagonist activity for A₁ adenosine receptors (A₁AR). They may have therapeutically use as cognitive enhancers , antidementia drugs (e.g. for Alzheimer's disease and cerebrovascular dementia), psychostimulants, antidepressant drugs and ameliorants of cerebral function⁹. Further more, a large number of pyrimidine derivatives are reported to exhibit antimycobacterial¹⁰, antitumor¹¹, antiviral¹², anticancer¹³, antiinflammatory¹⁴, analgesic¹⁵, antifolate¹⁶, antimicrobial¹⁷, antifungal¹⁸, antiproliferative¹⁹ and antihistaminic²⁰ activities.

Due to various biodynamic activities of pyrazolo [3,4-d] pyrimidines ,one pot synthesis of 3-Amino-4-Aryl-6-Mercapto-3a,4-Dihydro-1H-Pyrazolo[3,4-d] Pyrimidines[IIIa-n] have been undertaken by the condensation of 4-amino-5-cyano-6-aryl-2- mercapto-5,6-dihydro pyrimidines with hydrazine hydrate in ethanol. The product (IIIa-n) were assayed for their in vitro biological assay like antibacterial activity towards Gram positive and Gram negative bacterial strain and antifungal activity towards *Aspergillus niger* and *Candida albicans* at different concentration for their MIC values. The biological activities of the synthesized compounds were compared with standard drugs [Table 2]. The physical constant, antimicrobial and antimycobacterial activities of compounds (IIIa-n) recorded in Table 1, 2 and 3 respectively.

MATERIAL AND METHODS

Melting points were determined routinely in open capillary tube and are uncorrected. The completion of reaction was routinely checked by TLC on silica gel-G plates of 0.5mm thickness and spots were located by iodine. Elemental analyses of the newly synthesized compounds was carried out on Carlo Reba 1108 analyzer and are found within the range of theoretical value. IR spectra were recorded on Shimadzu-8400 FT-IR spectrometer in Ker (Δ in cm^{-1}). ^1H NMR spectra were recorded in CDCl_3 on a Bruker DRX-300 at 300 MHz. EI-MS spectra were recorded on Shimadzu GC-MS QP-2010 by Electron Impact method. In all the compounds, the molecular weights were found to be 43 m/z less than the molecular ion peak. No particular fragmentation pattern is observed from the spectra.

General Method for Synthesis of 3-Amino-4-Aryl-6-Mercapto-3a, 4-Dihydro-1H-Pyrazolo [3, 4-d] Pyrimidines (III a-n)

A mixture of 4-amino-5-cyano-6-aryl-2-mercapto-5, 6-dihydro pyrimidines (0.01mole) with hydrazine hydrate (0.01mole) in ethanol (30ml) under reflux for a specific period. The reaction mixture was kept at room temperature for 3 hrs.

The product was isolated and crystallized from a suitable solvent to give the desired product (IIIa-n).

3-Amino-4-(1'-N-Phenyl-3'-Methyl-5'-Chloro-Pyrazol-4'-YL)-6-Mercapto-3a,4-Dihydro-1H-Pyrazolo[3,4-d] Pyrimidines(III n)

IR: 3042(C-H) str.Aromatic), 1506 (C=C ring skeletal vib. Of pyrimidine), 1454 (C=N ring skeletal vib. pyrimidine), 2929(C-H str.asym.), 2839 (C-H sym.), 1409(C-H sym.), 1454(C-H def.asym.), 3417(N-H str.), 3375 (N-H str.), 1598 (N-H def.), 1290 (C-N str.), 1598 (C=N str.of pyrazol), 1572 (N-N def.of pyrazol), 1109(C-N str.of Pyrazol), 813 (C-Cl str.)

^1H -NMR (DMSO+ CDCl_3 , δ ppm): 2.41(3H,-CH₃), 5.73 (1H, -CH), 7.16-7.63(6H, Ar-H+CH+NH+SH), 7.96-8.02(2H,-NH₂)

MASS spectra: The mass spectrum fragmentation shows molecular ion (M^+) peak at $m/z=360$ was consistent with molecular formula $\text{C}_{15}\text{H}_{14}\text{N}_7\text{S}$

3-amino-3a, 4-dihydro-4-phenyl-1H-pyrazolo [3, 4-d] pyrimidine-6-thiol(III-a)

IR: 3004(C-H) str.Aromatic), 1504 (C=C

Table 1: Physical and analytical data

S. No.	R	X	Molecular Formula	m.p. °C	Yield (%)	R _f Value	% of Nitrogen	
							Calcd.	Found
III a	C ₆ H ₅	S	C ₁₁ H ₁₁ N ₅ S	140	61	0.62	28.57/28.52	
III b	2-Cl-C ₆ H ₄	S	C ₁₁ H ₁₀ N ₅ SCI	144	63	0.58	25.04/25.00	
III c	4-Cl-C ₆ H ₄	S	C ₁₁ H ₁₀ N ₅ SCI	158	48	0.49	25.04/24.99	
III d	3-Br-C ₆ H ₄	S	C ₁₁ H ₁₀ N ₅ SBr	165	51	0.51	21.67/21.61	
III e	3-NO ₂ -C ₆ H ₄	S	C ₁₁ H ₁₀ N ₅ O ₂ S	175	46	0.53	27.63/27.57	
III f	3-C ₆ H ₅ -O-C ₆ H ₄	S	C ₁₇ H ₁₅ N ₅ OS	138	54	0.50	20.77/20.71	
III g	4-OCH ₃ -C ₆ H ₄	S	C ₁₂ H ₁₃ N ₅ OS	147	50	0.63	25.45/25.40	
III h	2-OH-C ₆ H ₄	S	C ₁₁ H ₁₁ N ₅ OS	172	67	0.64	26.81/26.76	
III i	4-OH-C ₆ H ₅	S	C ₁₁ H ₁₁ N ₅ SO	230	52	0.52	26.81/26.8	
III j	C ₆ H ₄ -CH=CH	S	C ₁₃ H ₁₃ N ₅ S	151	56	0.55	25.83/25.80	
III k	4-CH ₃ S-C ₆ H ₄	S	C ₁₂ H ₁₃ N ₅ S ₂	168	48	0.57	24.05/23.97	
III l	á- C ₆ H ₃ O	S	C ₉ H ₉ N ₅ OS	250	68	0.58	29.78/29.73	
III m	4-N-(CH ₃) ₂ -C ₆ H ₄	S	C ₁₃ H ₁₆ N ₆ S	180	74	0.61	29.16/29.11	
III n	1-N-C ₆ H ₅ -3-CH ₃ -5Cl-C ₃ N ₄	S	C ₁₅ H ₁₄ N ₇ SCI	128	68	0.62	27.26/27.20	

TLC Solvent systems: Acetone: Benzene= 1:9

ring skeletal vib. Of pyrimidine) ,1456(C=N ring skeletal vib. pyrimidine), 2925(C-H str.asym.), 2837 (C-H sym.), 1365(C-H sym.), 3471(N-H str.), 3135 (N-H str.), 1581 (N-H def.) ,1355 (C-N str.), 1651 (C=N str.of pyrazol), 1620 (N-N def.of pyrazol), 1165(C-N str.of Pyrazol).

$^1\text{H-NMR}$ (DMSO+ CDCl_3 , δ ppm): 5.62 (1H, -CH), 6.74-7.93(9H, Ar-H+CH+ NH_2 +SH).

MASS spectra: The mass spectrum fragmentation shows molecular ion (M^+) peak at $m/z=245.0$ was consistent with molecular formula $\text{C}_{11}\text{H}_{11}\text{N}_5\text{S}$

Table 2: Antimicrobial Activity of 3-Amino-4-Aryl-6-Mercapto-3a, 4-Dihydro-1H-Pyrazolo [3, 4-d] Pyrimidines (III a-n)

Compound	R	Antibacterial activity				Antifungal activity	
		<i>S.pyogens</i> MTCC- 442	<i>S.aureus</i> MTCC-96	<i>E.coli</i> MTCC- 443	<i>B.subtillis</i> MTCC- 441	<i>C.albicans</i> MTCC- 227	<i>A.niger</i> MTCC- 282
III a	C_6H_5	200	200	500	800	-	200
III b	2-Cl- C_6H_4	25	100	200	500	500	800
III c	4-Cl- C_6H_4	-	50	800	-	100	50
III d	3-Br- C_6H_4	800	100	25	200	200	500
III e	3- NO_2 - C_6H_4	50	50	100	-	50	-
III f	3- C_6H_5 -O- C_6H_4	200	200	800	100	800	200
III g	4-O CH_3 - C_6H_4	25	25	-	25	-	100
III h	2-OH- C_6H_4	-	500	50	50	200	800
III i	4-OH- C_6H_5	800	100	200	200	200	-
III j	C_6H_4 -CH=CH	100	-	-	800	800	500
III k	4- CH_3 - C_6H_4	500	500	100	200	-	-
III l	á- $\text{C}_4\text{H}_3\text{O}$	100	200	200	500	500	800
III m	4-N-(CH_3) $_2$ - C_6H_4	200	200	100	200	800	-
III n	1-N- C_6H_5 -3- CH_3 -5Cl- C_3N_4	100	200	25	500	500	-

Comparative activity of (III a-n) with known chosen standard drugs


Standard Drug	Antibacterial activity				Antifungal activity	
	<i>S.pyogens</i> MTCC-442	<i>S.aureus</i> MTCC-96	<i>E.coli</i> MTCC- 443	<i>B.subtillis</i> MTCC- 441	<i>C.albicans</i> MTCC- 227	<i>A.niger</i> MTCC- 282
IIIb(25), IIIe(50) IIIg(25)	IIIc(50), IIIe(50) IIIg(25)	IIIc(50), IIIe(50) IIIg(25)	IIIc(50), IIIe(50) IIIh(50)	IIIg(25) IIIg(25) IIIh(50)	IIIe(50)	IIIc(50)
Ampicillin	30	20	30	30	-	-
Amoxycillin	20	20	20	20	-	-
Cifalexin	20	30	35	20	-	-
Erythromycin	30	35	20	20	-	-
Chlotrimazole	-	-	-	-	20	20
Griseofulvin	-	-	-	-	30	20

N.B. :(-): No activity

3-amino-3a,4-dihydro-4-(methylthio)-1H-pyrazolo[3,4-d]pyrimidine-6-thiol(III-j)

IR: 3030(C-H) str.Aromatic), 1512 (C=C ring skeletal vib. Of pyrimidine) ,1456(C=N ring skeletal vib. pyrimidine), 2920(C-H str.asym.), 2852 (C-H sym.), 1383(C-H sym.), 3435(N-H str.), 3375 (N-H str.), 1311 (N-H def.) ,1178 (C-N str.), 1662 (C=N str.of pyrazol), 1583(N-N def.of pyrazol), 1178(C-N str.of Pyrazol).

¹H-NMR (DMSO+ CDCl₃, δ ppm): 2.47(3H, SCH₃), 5.95 (1H, -CH), 6.71-8.70(9H, Ar-H+CH+NH₂+SH)



Scheme

Where R=Aryl

growth of the test bacteria. Each purified compound was dissolved in DMF sterilized by filtration by using sintered glass filter and stored at 4°C. Each agent was then added to molten nutrient agar in the following concentration(µg/ml): 0 (control), 25,50,100,200,500,800 and poured into sterile Petri dished. The pH of the media was maintained at 7.2-7.4. The inoculums consisted of an overnight growth broth culture of a bacterium diluted in such a manner that a 2mm (internal diameter) loopful of the culture contain 10⁰ colony-forming unit (CFU). These were then spot inoculated on nutrient agar plates containing increasing amount of a compound, incubated at 37°C up to 24 hrs. for determination of the minimum inhibitory concentration (MIC)⁹¹⁻⁹². The antibacterial activity of the compounds (III a-n) was compared with known standard reference drugs like Ampicillin, Ciprofloxacin, Chloramphenical, Griseofulvin, at same concentration. The moderate and comparable antibacterial activities of compound are recorded.

Antifungal Activity

Aspergillus niger MTCC-282 and *Candida albicans* MTCC-227 were employed for testing fungicidal activity using cup plate method. The

MASS spectra: The mass spectrum fragmentation shows molecular ion (M⁺) peak at m/z=271.0 was consistent with molecular formula C₁₃H₁₃N₅S.

Antimicrobial Activity

Antimicrobial was carried out by using cup-plate method which has been described as under.

Antibacterial Activity

Gram positive bacteria were grown in nutrient broth and Gram negative bacteria in Peptone water (PW, 1% bacteriological peptone and 0.5% NaCl) for 24 hours; this gave an optimum

cultures were maintained on Sabouraud's agar for 72 hours this gave an optimum growth of the test fungal spores Each purified compound was dissolved in DMF sterilized by filtration by using sintered glass filter and stored at 4°C. Each agent was then added to Sabouraud's agar in the following concentration(µg/ml): 0 (control), 25, 50, 100, 200, 500, 800 and poured into sterile Petri dished.. The inoculums consisted of an overnight growth broth culture of a bacterium diluted in such a manner that a 2mm (internal diameter) loopful of the culture contain 10⁵ colony-forming units (CFU). These were then spot inoculated on Sabouraud's agar plates containing increasing amount of a compound, incubated at 37°C up to 48 hrs. For determination of the minimum inhibitory concentration (MIC)⁹¹⁻⁹². Th MIC value of test solutions are recorded in Table 2.

CONCLUSION

It was interesting to note that the reaction occurred immediately. This work demonstrates a very simple and efficient method for the synthesis of a well functionalized pyrazolo [3, 4-d] pyrimidines of biological importance in excellent yields.

REFERENCES

1. Petrie C.R., III, Cottam H.B., Mckerman P.A., Robins R.K. and Ravenkar G.R.; *J. Med. Chem.*, **28**: 1985 (1010)
2. Bhat G.A., Monestero J.G., Panzicz R.P., Worting L.L., and Towsemd L.B., *J. Med. Chem.*, **24**: 1165 (1981).
3. Zacharie B., Connolly T.P., Rel R., Attardo G., and Panney C.L., *Tetrahedron*, **52**: 2271 (1996).
4. E. Y. Sutcliffe, K. Y. Zee-Cheng, C. C. Cheng, R. K. Chem. 21, 969 (1984). Robins, *J. Med. Chem.* **5**: 588 (1962).
5. Hamilton, H. W.; Ortwine, D. F.; Worth, D. F.; Bristol, J. A. Synthesis and structure–activity relationships of pyrazolo [4, 3-d] pyrimidin-7-ones as adenosine receptor antagonists. *J. Med. Chem.* **30**, 91-96 (1987).
6. Davies, L. P.; Chow, S. C.; Skerrit, J. H.; Brown, D. J.; Johnston, G. A. R. Pyrazolo[3,4-d]pyrimidines as adenosine antagonists. *Life Sci.*, **34**: 2117-2128 (1984).
7. Poulsen, S. A.; Quinn, R. J. Synthesis and structure–activity relationship of pyrazolo [3, 4-d] pyrimidines: Potent and selective adenosine A1 receptor antagonists. *J. Med. Chem.*, **39**: 4156-4161 (1996).
8. Harden, F. A.; Quinn, R. J.; Scammells, P. J. Synthesis and adenosine receptor affinity of a series of pyrazolo [3, 4-d] pyrimidine analogs of 1-methylisoguanosine. *J. Med. Chem.*, **34**: 2892–2898 (1991).
9. Ralevic, V.; Burnstock, G. Receptors for purines and pyrimidines. *Pharmacol. Rev.*, **50**, 413–492 (1998).
10. A. Kumar, S. Sinha and M. S. Chauhan, Synthesis of novel antimyco-bacterial combinatorial libraries of structurally diverse substituted pyrimidines by three-component solid phase reactions, *Bioorg. Med. Chem. Lett.* **12**, 667–670 (2002).
11. P. G. Baraldi, M. G. Pavani, M. Nunez, P. Brigidi, B. Vitali, R. Gambari and R. Romagnoli, Antimicrobial and antitumor activity of N-heteroimine-1,2,3-dithiazoles and their transformation in triazolo-, imidazo- and pyrazolopyrimidines, *Bioorg. Med. Chem.* **10**: 449-456 (2002).
12. M. N. Nasr and M. M. Gineinah, Pyrido[2,3-d]pyrimidines and pyrimido [5',4':5,6]pyrido[2,3-d]pyrimidines as new antiviral agents: Synthesis and biological activity, *Arch. Pharm.* **335**: 289–295 (2002).
13. S. M. Sondhi, M. Johar, S. Rajvanshi, S. G. Dastidar, R. Shukla, R. Raghubir and J. W. Lown, Anticancer, anti-inflammatory and analgesic activity evaluation of heterocyclic compounds synthesized by the reaction of 4-isothiocyanato-4-methylpentan-2-one with substituted o-phenylenediamines, o-diaminopyridine and (un)substituted o-diaminopyrimidines, *Aust. J. Chem.* **54**: 69-74 (2001).
14. A. Gangjee, A. Vidwans, E. Elzein, J. J. Mc Guire, S. F. Queener and R. L. Kisliuk, Synthesis, antifolate and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d] pyrimidines *J. Med. Chem.* **44**: 1993–2003 (2001).
15. Kumar, G. Singh and A. K. Yadav, Synthesis of some new pyrido[2,3-d]pyrimidines and their ribofuranosides as possible antimicrobial agents, *Heteroat. Chem.* **12**: 52-56 (2001).
16. G. Mangalagiu, M. Ungureanu, G. Grosu, I. Mangalagiu and M. Petrovanu, New pyrrolo-pyrimidine derivatives with antifungal or antibacterial properties, *Ann. Pharm. Fr.* **59**: 139-140 (2001).
17. J. Griffon, J. A. Montgomery and J. A. Secrist, Synthesis and antiproliferative activity of some 4'-C-Hydroxymethyl-?-and -?-D-arabino-pentofuranosyl pyrimidine nucleosides, *Nucleosides Nucleotides.* **20**, 649-652 (2001).
18. C. J. Shishoo, V. S. Shirsath, I. S. Rathod, M. J. Patil and S. S. Bhargava, Design, synthesis and antihistaminic (H1) activity of some condensed 2-(substituted) arylaminoethyl-pyrimidin-4(3H)-ones, *Arzneim. Forsch.* **51**: 221–231 (2001).
19. O. Bruno, C. Brullo, S. Schenone, A. Ranise, F. Bondavalli, E. Barocelli, M. Tognolini, F. Magnanini and V. Bollabeni, Progress in 5H-[1]benzopyrano[4,3-d]pyrimidin-5-amine series: 2-methoxy derivatives effective as

- antiplatelet agents with analgesic activity, *Farmaco*. **57**: 753-758 (2002).
20. C. Mustazza, M. R. D. Guidice, A. Borioni and F. Gatta, Synthesis of pyrazolo[1,5-a]-1,2,4-triazolo[1,5-a]- and imidazo[1,2-a]pyrimidines related to Zaleplon, a new drug for the treatment of insomnia, *J. Heterocycl. Chem.* **38**: 1119-1130 (2001).
21. a) F. Yoneda, M. Higuchi, T. Nagamatsu, *J. Am. Chem. Soc.* **96**: 5607 (1974);
b) F. Yoneda, T. Naga-matsu, T. Nagamura, K. Senga, *J. Chem. Soc. PerkinTrans. 1*: 765 (1977);
c) F. Yoneda, T. Nagamatsu, *Synthesis*. 300 (1973).
22. Y. Maki, K. Izuka, M. Suzuki, *J. Chem. Soc., Chem. Commun.* 1442 (1971).
23. H. Kanazawa, S. Nishigaki, K. Singa, *J. Heterocycl. Chem.* **21**: 969 (1984).